Try Fund Library Premium
Free with a 30 day trial!
Gain access to
- Unlimited Watchlists
- Advanced Search Filtering
- Fund Comparisons
- Portfolio Scenarios
- Customizable PDF Reports
- Portfolio Rebalancer new
CI Global Health Sciences Corporate Class (Series A shares)
Health Care Equity
Click for more information on Fundata’s FundGrade
FundGrade E
Click for more information on Fundata’s FundGrade.
Click for more information on Fundata’s ESG Grade
Fundata ESG Grade A
Click for more information on Fundata’s ESG Grade.
FundGrade A+® Rating Recipient
2013
Click for more information on Fundata’s FundGrade
|
NAVPS (05-13-2026) |
$48.57 |
|---|---|
| Change |
$0.12
(0.24%)
|
As at April 30, 2026
As at April 30, 2026
As at April 30, 2026
Loading......
Legend
Compare Options
Fund Returns
Inception Return (July 23, 1996): 6.83%
| Row Heading | Return | Annualized Return | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 Mth | 3 Mth | 6 Mth | YTD | 1 Yr | 2 Yr | 3 Yr | 4 Yr | 5 Yr | 6 Yr | 7 Yr | 8 Yr | 9 Yr | 10 Yr | |
| Fund | -3.69% | -10.32% | -7.16% | -11.19% | -3.40% | -6.38% | -2.24% | 0.41% | -1.85% | 0.74% | 1.38% | 1.71% | 1.65% | 1.97% |
| Benchmark | -2.20% | -5.11% | -0.92% | -4.87% | 5.78% | 3.80% | 4.47% | 5.87% | 5.46% | 5.98% | 7.70% | 8.37% | 7.92% | 8.80% |
| Category Average | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Category Rank | 52 / 53 | 51 / 51 | 51 / 51 | 51 / 51 | 44 / 51 | 49 / 49 | 43 / 43 | 37 / 41 | 38 / 39 | 36 / 36 | 35 / 35 | 32 / 32 | 29 / 29 | 29 / 29 |
| Quartile Ranking | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
Monthly Return
| Return % | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Jan | Feb | Mar | Apr |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund | -7.10% | 1.21% | -1.06% | 3.70% | 1.07% | 6.72% | 6.85% | -2.16% | -0.98% | 0.46% | -7.31% | -3.69% |
| Benchmark | -3.48% | 0.91% | -0.60% | 4.16% | 2.38% | 3.42% | 7.21% | -2.85% | 0.25% | 3.41% | -6.17% | -2.20% |
Best Monthly Return Since Inception
14.15% (June 2009)
Worst Monthly Return Since Inception
-11.87% (October 2008)
Calendar Return (%)
| Return % | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Fund | -19.15% | 6.44% | 1.11% | 12.00% | 11.20% | -0.08% | -1.18% | 2.65% | 1.60% | 3.41% |
| Benchmark | -8.68% | 14.01% | 11.82% | 17.06% | 13.59% | 15.28% | -1.72% | 1.42% | 9.95% | 9.64% |
| Category Average | - | - | - | - | - | - | - | - | - | - |
| Quartile Ranking | 4 | 4 | 4 | 4 | 3 | 4 | 3 | 2 | 4 | 4 |
| Category Rank | 29/ 29 | 28/ 29 | 29/ 32 | 32/ 34 | 18/ 35 | 37/ 38 | 21/ 40 | 17/ 41 | 43/ 48 | 42/ 50 |
Best Calendar Return (Last 10 years)
12.00% (2019)
Worst Calendar Return (Last 10 years)
-19.15% (2016)
Asset Allocation
| Name | Percent |
|---|---|
| US Equity | 84.91 |
| International Equity | 14.80 |
| Cash and Equivalents | 0.30 |
Sector Allocation
| Name | Percent |
|---|---|
| Healthcare | 96.47 |
| Exchange Traded Fund | 3.23 |
| Cash and Cash Equivalent | 0.29 |
| Other | 0.01 |
Geographic Allocation
| Name | Percent |
|---|---|
| North America | 85.15 |
| Europe | 14.84 |
| Asia | 0.00 |
| Other | 0.01 |
Top Holdings
| Name | Percent |
|---|---|
| Eli Lilly and Co | 13.61 |
| AstraZeneca PLC | 8.17 |
| Thermo Fisher Scientific Inc | 8.09 |
| Johnson & Johnson | 7.59 |
| IQVIA Holdings Inc | 6.29 |
| DexCom Inc | 5.46 |
| UnitedHealth Group Inc | 5.21 |
| Intuitive Surgical Inc | 5.19 |
| Danaher Corp | 4.93 |
| Stryker Corp | 4.73 |
Equity Style
Fixed Income Style
Risk vs Return (3 Yr)
CI Global Health Sciences Corporate Class (Series A shares)
Median
Other - Health Care Equity
3 Yr Annualized
| Standard Deviation | 13.42% | 12.52% | 14.69% |
|---|---|---|---|
| Beta | 1.10 | 0.94 | 1.04 |
| Alpha | -0.07 | -0.07 | -0.07 |
| Rsquared | 0.87% | 0.79% | 0.68% |
| Sharpe | -0.37 | -0.32 | 0.08 |
| Sortino | -0.43 | -0.44 | 0.00 |
| Treynor | -0.05 | -0.04 | 0.01 |
| Tax Efficiency | - | - | 74.94% |
| Volatility |
|
|
|
Risk Rating
Annualized Key Ratio Period Comparison
| Key Ratio | 1 Yr | 3 Yr | 5 Yr | 10 Yr |
|---|---|---|---|---|
| Standard Deviation | 15.92% | 13.42% | 12.52% | 14.69% |
| Beta | 1.12 | 1.10 | 0.94 | 1.04 |
| Alpha | -0.09 | -0.07 | -0.07 | -0.07 |
| Rsquared | 0.86% | 0.87% | 0.79% | 0.68% |
| Sharpe | -0.29 | -0.37 | -0.32 | 0.08 |
| Sortino | -0.45 | -0.43 | -0.44 | 0.00 |
| Treynor | -0.04 | -0.05 | -0.04 | 0.01 |
| Tax Efficiency | - | - | - | 74.94% |
Fundata ESG Metrics
Fundata ESG Score
The E, S, and G scores are averaged for each security in the portfolio, to arrive at an ESG score for each security. We take the portfolio weighted average of the ESG scores for each fund and rank them against their peers to arrive at the Fundata ESG Score from 0-100.
Fundata E Score
Three scores under the Environment bucket are averaged to yield the Fundata Environment Score for each fund from 0-100: (1) Pollution Prevention, (2) Environmental Transparency, (3) Resource Efficiency.
Fundata S Score
Six scores under the Social bucket are averaged to yield the Fundata Social Score for each fund from 0-100. (1) Compensation and Satisfaction, (2) Diversity and Rights, (3) Education and Work Conditions, (4) Community and Charity, (5) Human Rights, (6) Sustainability Integration.
Fundata G Score
Three scores under the governance bucket are averaged to yield the Fundata Governance Score for each fund from 0-100: (1) Board Effectiveness, (2) Management Ethics, (3) Disclosure and Accountability.
Powered by OWL Analytics. For more information, please contact Fundata Canada.
Fund Details
| Start Date | July 23, 1996 |
|---|---|
| Instrument Type | Mutual Fund |
| Share Class | Commission Based Advice |
| Legal Status | Corporation |
| Sales Status | Open |
| Currency | CAD |
| Distribution Frequency | Quarterly |
| Assets ($mil) | $129 |
Fund Codes
| FundServ Code | Load Code | Sales Status |
|---|---|---|
| CIG14648 | ||
| CIG14748 | ||
| CIG14848 | ||
| CIG1701 | ||
| CIG201 | ||
| CIG701 |
Investment Objectives
This fund’s objective is to obtain maximum long-term capital growth. It invests primarily in equity and equity-related securities of companies around the world that specialize in the health care or medical industry. This includes companies that provide goods and services to these companies and companies that the portfolio adviser believes would benefit from developments in the health sciences industry.
Investment Strategy
The portfolio advisor identifies companies that have the potential for strong growth in their industry and then considers the impact of economic trends. The portfolio advisor may use techniques such as fundamental analysis to assess growth potential. This means evaluating the financial condition and management of each company, its industry and the overall economy.
Portfolio Management
| Portfolio Manager |
CI Global Asset Management
|
|---|---|
| Sub-Advisor |
- |
Management and Organization
| Fund Manager |
CI Global Asset Management |
|---|---|
| Custodian |
CIBC Mellon Trust Company |
| Registrar |
CI Global Asset Management |
| Distributor |
- |
Investment Minimums
| RSP Eligible | Yes |
|---|---|
| PAC Allowed | Yes |
| PAC Initial Investment | 50 |
| PAC Subsequent | 50 |
| SWP Allowed | Yes |
| SWP Min Balance | 5,000 |
| SWP Min Withdrawal | 50 |
Fees
| MER | 2.34% |
|---|---|
| Management Fee | 1.90% |
| Load | Choice of Front or No Load |
| FE Max | 5.00% |
| DSC Max | - |
| Trailer Fee Max (FE) | 1.00% |
| Trailer Fee Max (DSC) | 0.50% |
| Trailer Fee Max (NL) | - |
| Trailer Fee Max (LL) | - |
Try Fund Library Premium
Free with a 30 day trial!
Gain access to
- Unlimited Watchlists
- Advanced Search Filtering
- Fund Comparisons
- Portfolio Scenarios
- Customizable PDF Reports
- Portfolio Rebalancer new
